V. A. Fefelova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
V. A. Fefelova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Elena Vladimirovna Reznik
Pirogov Russian National Research Medical University
5 shared publications - L. Kh. Alieva
Pirogov Russian National Research Medical University
5 shared publications В. А. Фефелова
ФГАОУ ВО РНИМУ имени Н.И. Пирогова Минздрава России
2 shared publications- E. V. Aranovich
Yusupov Hospital (LLC «Neuro-Clinic»)
1 shared publication - Georgiy N. Golukhov
Pirogov Russian National Research Medical University, Moscow, Russia
1 shared publication K. Sh. Azizova
Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- 1 October 2026
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 3 (3)
Cardiogenic Encephalopathy in Patients with Heart Failure: А Review
INTRODUCTION. The increasing prevalence of chronic heart failure in the population inevitably correlates with an increase in cognitive impairment caused by chronic cerebral ischemia. Cardiogenic encephalopathy leads to memory impairment, which is a significant factor affecting quality of life, and poor adherence to therapy is likely to increase the risk of serious cardiovascular events. This review examines the concept and currently available data on the mechanisms of development, epidemiology, and prognostic significance of cognitive encephalopathy in patients with heart failure. AIM. To present current data on the relationship between heart failure and cognitive impairment, the mechanisms underlying cardiogenic encephalopathy, its diagnostic methods, and opportunities for personalized therapy. MATERIALS AND METHODS. A search for relevant information for the period 2021–2026 was conducted. A study using PubMed and eLIBRARY.RU databases focused on cognitive impairment in patients with chronic heart failure, cardiogenic encephalopathy, differential diagnosis, and metabolic neuroprotection. RESULTS AND DISCUSSION. Cognitive impairment significantly impacts mortality in patients with chronic heart failure and is considered an independent risk factor for adverse outcomes. It is important to diagnose cardiogenic encephalopathy as early as possible and consider its presence when managing patients with chronic heart failure. CONCLUSION. Further study is needed to identify methods for preventing the development and progression of brain damage in patients with heart failure. KEYWORDS: chronic heart failure, cardiovascular diseases, cardiogenic encephalopathy, cognitive impairments
- 1 October 2026
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 3 (3)
Cardiogenic Encephalopathy in Patients with Heart Failure: А Review
INTRODUCTION. The increasing prevalence of chronic heart failure in the population inevitably correlates with an increase in cognitive impairment caused by chronic cerebral ischemia. Cardiogenic encephalopathy leads to memory impairment, which is a significant factor affecting quality of life, and poor adherence to therapy is likely to increase the risk of serious cardiovascular events. This review examines the concept and currently available data on the mechanisms of development, epidemiology, and prognostic significance of cognitive encephalopathy in patients with heart failure. AIM. To present current data on the relationship between heart failure and cognitive impairment, the mechanisms underlying cardiogenic encephalopathy, its diagnostic methods, and opportunities for personalized therapy. MATERIALS AND METHODS. A search for relevant information for the period 2021–2026 was conducted. A study using PubMed and eLIBRARY.RU databases focused on cognitive impairment in patients with chronic heart failure, cardiogenic encephalopathy, differential diagnosis, and metabolic neuroprotection. RESULTS AND DISCUSSION. Cognitive impairment significantly impacts mortality in patients with chronic heart failure and is considered an independent risk factor for adverse outcomes. It is important to diagnose cardiogenic encephalopathy as early as possible and consider its presence when managing patients with chronic heart failure. CONCLUSION. Further study is needed to identify methods for preventing the development and progression of brain damage in patients with heart failure. KEYWORDS: chronic heart failure, cardiovascular diseases, cardiogenic encephalopathy, cognitive impairments
- 15 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9S)
Hyperammonemia as an interdisciplinary problem: from pathogenesis to therapy. A literature review
In the human body, ammonia is produced as a result of the metabolism of nitrogen-containing compounds. An increase in the blood concentration of ammonia above the normal range (21-50 μmol/L) is referred to as hyperammonemia. Ammonia is a toxic compound. Although its blood concentration is relatively low in healthy individuals, even a slight increase can have negative health effects, particularly on the central nervous system. Clinical manifestations vary depending on the degree of ammonia elevation and include irritability, vomiting, ataxia, seizures, and coma. This literature review summarizes current data on the mechanisms of ammonia formation, classification, and pathogenetic mechanisms of hyperammonemia effect on various organ systems. Particular attention is paid to analyzing the effectiveness of therapeutic strategies aimed at reducing blood ammonia concentrations. The importance of early treatment to minimize the risk of irreversible nervous system damage is emphasized.
- 15 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9S)
Hyperammonemia as an interdisciplinary problem: from pathogenesis to therapy. A literature review
In the human body, ammonia is produced as a result of the metabolism of nitrogen-containing compounds. An increase in the blood concentration of ammonia above the normal range (21-50 μmol/L) is referred to as hyperammonemia. Ammonia is a toxic compound. Although its blood concentration is relatively low in healthy individuals, even a slight increase can have negative health effects, particularly on the central nervous system. Clinical manifestations vary depending on the degree of ammonia elevation and include irritability, vomiting, ataxia, seizures, and coma. This literature review summarizes current data on the mechanisms of ammonia formation, classification, and pathogenetic mechanisms of hyperammonemia effect on various organ systems. Particular attention is paid to analyzing the effectiveness of therapeutic strategies aimed at reducing blood ammonia concentrations. The importance of early treatment to minimize the risk of irreversible nervous system damage is emphasized.
- Open Access
- 13 August 2026
- Published by Northern State Medical University in The Russian Archives of Internal Medicine
- Vol. 16 (4) , 305-311
Kikuchi-Fujimoto’s Disease on The Background of Primary Immunodeficiency and Multiple Sclerosis: A Clinical Case
For the first time, a combination of Kikuchi-Fujimoto’s disease with general variable immune deficiency and multiple sclerosis has been described. The patient’s primary immunodeficiency, accompanied by frequent and severe exacerbations of chronic diseases, led to a protracted diagnostic search. The case highlights the importance of timely morphological examination in persistent lymphadenopathy, even in patients with known immune disorders.
- 13 August 2026
- Published by Northern State Medical University in The Russian Archives of Internal Medicine
- Vol. 16 (4) , 305-311
Open AccessKikuchi-Fujimoto’s Disease on The Background of Primary Immunodeficiency and Multiple Sclerosis: A Clinical Case
For the first time, a combination of Kikuchi-Fujimoto’s disease with general variable immune deficiency and multiple sclerosis has been described. The patient’s primary immunodeficiency, accompanied by frequent and severe exacerbations of chronic diseases, led to a protracted diagnostic search. The case highlights the importance of timely morphological examination in persistent lymphadenopathy, even in patients with known immune disorders.
- Open Access
- 13 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (8S) , 6677
Restrictive cardiomyopathy after SARS-CoV-2-related myocarditis: the role of genetic predisposition. A case report
Restrictive cardiomyopathy (RCM) is a rare disease characterized by impaired diastolic function o due to increased myocardial stiffness. The prognosis for RCM is often unfavorable, especially in children. In most cases, the disease is genetic in nature. Clinical manifestations are varied. This case highlights the complexity of diagnosing and treating RCM after SARS-CoV-2-related myocarditis.
- 13 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (8S) , 6677
Open AccessRestrictive cardiomyopathy after SARS-CoV-2-related myocarditis: the role of genetic predisposition. A case report
Restrictive cardiomyopathy (RCM) is a rare disease characterized by impaired diastolic function o due to increased myocardial stiffness. The prognosis for RCM is often unfavorable, especially in children. In most cases, the disease is genetic in nature. Clinical manifestations are varied. This case highlights the complexity of diagnosing and treating RCM after SARS-CoV-2-related myocarditis.
- 15 May 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (2) , 83-90
Dilated cardiomyopathy in a patient with Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe X-linked hereditary disorder resulting from mutations in dystrophin gene (DMD) and leading to progressive degeneration of skeletal and cardiac muscles. Classic clinical phenotype is characterized by progressive motor dysfunction and muscle weakness, while cardiac involvement typically presents as dilated cardiomyopathy accompanied by arrhythmias and conduction disturbances. This report describes a patient who developed severe dilated cardiomyopathy at 12 years of age with left ventricular ejection fraction 21%. Despite optimal therapy the patient experienced recurrent heart failure decompensations (up to 8 times annually) between 12 and 18 years of age. Genetic analysis at 18 years of age identified pathogenic DMD gene mutation, and Duchenne muscular dystrophy was diagnosed. Although heart transplantation was deliberated, the patient succumbed before evaluation by a transplant team. This case underscores the importance of early etiological diagnosis in dilated cardiomyopathy, awareness of cardiologists regarding Duchenne muscular dystrophy and timely initiation of disease-specific treatments. Detection of DMD mutation warrants comprehensive cardiovascular screening, regular cardiological follow-up and genetic counseling.
- 15 May 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (2) , 83-90
Dilated cardiomyopathy in a patient with Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe X-linked hereditary disorder resulting from mutations in dystrophin gene (DMD) and leading to progressive degeneration of skeletal and cardiac muscles. Classic clinical phenotype is characterized by progressive motor dysfunction and muscle weakness, while cardiac involvement typically presents as dilated cardiomyopathy accompanied by arrhythmias and conduction disturbances. This report describes a patient who developed severe dilated cardiomyopathy at 12 years of age with left ventricular ejection fraction 21%. Despite optimal therapy the patient experienced recurrent heart failure decompensations (up to 8 times annually) between 12 and 18 years of age. Genetic analysis at 18 years of age identified pathogenic DMD gene mutation, and Duchenne muscular dystrophy was diagnosed. Although heart transplantation was deliberated, the patient succumbed before evaluation by a transplant team. This case underscores the importance of early etiological diagnosis in dilated cardiomyopathy, awareness of cardiologists regarding Duchenne muscular dystrophy and timely initiation of disease-specific treatments. Detection of DMD mutation warrants comprehensive cardiovascular screening, regular cardiological follow-up and genetic counseling.
- 28 March 2026
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 16 (2)
Hyperuricemia and cardiovascular risk: gut microbiota as a key link in pathogenesis and a new target for therapy
Hyperuricemia is a significant and independent risk factor for cardiovascular diseases. In recent years, scientists have been paying attention to the gut microbiota and its impact on various processes in the human body. Currently, there is evidence of the important role of the microbiota in the pathogenesis of hyperuricemia. An increase in the number of pathogenic microflora contributes to chronic inflammation and an increase in uric acid levels through the mechanisms of purine metabolism. The purpose of this review is to analyze and systematize current data on the impact of the intestinal microbiota on the pathogenesis of hyperuricemia and cardiovascular risk. The article discusses promising methods for correcting hyperuricemia, such as lifestyle modification, fecal microbiota transplantation, probiotics, and postbiotics. The review highlights the need for further research on the microbiota as a key factor in the pathogenesis of hyperuricemia and the development of new and innovative therapeutic strategies.
- 28 March 2026
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 16 (2)
Hyperuricemia and cardiovascular risk: gut microbiota as a key link in pathogenesis and a new target for therapy
Hyperuricemia is a significant and independent risk factor for cardiovascular diseases. In recent years, scientists have been paying attention to the gut microbiota and its impact on various processes in the human body. Currently, there is evidence of the important role of the microbiota in the pathogenesis of hyperuricemia. An increase in the number of pathogenic microflora contributes to chronic inflammation and an increase in uric acid levels through the mechanisms of purine metabolism. The purpose of this review is to analyze and systematize current data on the impact of the intestinal microbiota on the pathogenesis of hyperuricemia and cardiovascular risk. The article discusses promising methods for correcting hyperuricemia, such as lifestyle modification, fecal microbiota transplantation, probiotics, and postbiotics. The review highlights the need for further research on the microbiota as a key factor in the pathogenesis of hyperuricemia and the development of new and innovative therapeutic strategies.